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Abstract
The prevalence of comorbid fibromyalgia syndrome in autoimmune rheumatic diseases 
is clinically significantly higher than is fibromyalgia syndrome in the general  population. 
By increasing pain sensitivity and fatigue, it disproportionately inflates subjective signs 
and symptoms, thereby obfuscating composite indices used to measure biological  disease 
activity, the degree of disability, and the quality of life. By modifying primary disease 
phenotype, it also interferes with diagnostic precision. This review documents its effects 
on rheumatoid arthritis, the spondyloarthropathies, and systemic lupus erythematosus; 
and offers a general remedial strategy.
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1. Introduction
Subjective symptoms such as patient global assessment of health (PtGA), fatigue,  tenderness 
of joints at palpation (TJC), and even patient report of functional ability encountered in 
the evaluation of rheumatic diseases are very important not only because they reflect the 
 individual patient’s impression of disease activity and degree of disability, but also because 
patients place great faith in them [1]. Patients’ estimation of pain, fatigue, and distress, which 
drive those subjective measures, is multidimensional, due to both biological disease activ-
ity as well as factors unrelated to disease-specific biological inflammation. Some of these 
factors include mechanical damage from comorbid osteoarthritis or disease-specific joint 
 destruction and neuropathy from other disease, psychosocial factors, and even idiopathic 
poor sleep  disorder. All of these factors can result in disproportionately higher subjective 
symptoms [2–4].
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Composite indices such as the disease activity score (DAS) models are widely used to 
 determine disease activity in clinical trials and everyday practice. Unfortunately, they may be 
misleading when used to evaluate apparent inflammatory activity in patients with comorbid 
chronic pain syndromes often coupled with psychological distress, which are synonymous 
with fibromyalgia syndrome (FMS). Comorbid FMS is associated with relative overestimation 
of subjective symptoms, which then inappropriately inflate the DAS models.
Fibromyalgia syndrome is comorbid in all rheumatic disease with prevalence as high as 
25% in rheumatoid arthritis (RA), and 30% in systemic lupus erythematosus (SLE) and the 
 spondyloarthropathies (SpA) [5–8]. The focus of this review will be on RA, SpA, and SLE.
1.1. Rheumatoid arthritis
In the past, when I spoke to rheumatologists about FMS, they often responded, “Why should 
I see patients with fibro? So many symptoms. And these patients with their personality 
 disorders on top of anxiety and depression just wear me down. They’re the worst.”
The easy moral response might be, “Because these patients come to you for care, and you took 
an oath.”
“I know, but why me?”
There are at least two other responses, both persuasive. The first appeals to the intellect. 
Fibromyalgia syndrome is a symptom complex at the severe end of a pain-distress spectrum 
[4, 9, 10]
It is a fascinating illness: a primary response to distress with demonstrated secondary process 
factors and dysfunction related to the endocrine [11] autonomic system[12], central nervous 
system [13], sleep quality [14], and arguably, even the immune system [15].
These process factors give rise to a plethora of symptoms including diffuse pain, fatigue, 
cognitive dysfunction, sleep disturbances, more severe morning stiffness, irritable bowel 
 syndrome (IBS), headaches, Raynaud-like phenomenon, sicca symptoms, paresthesias, 
 auditory dysfunction, bladder dysfunction, and among others [16–18].
The second is a practical response. The prevalence of FMS in the general population ranges 
from 2 to 8% [19–22]. As previously noted, the prevalence in rheumatic diseases is much 
higher. With practice, the clinician will become familiar with the FMS phenotype and be 
able to recognize it as a comorbidity in autoimmune rheumatic diseases. The reason that 
 recognition is so important is, as we will see, that comorbid FMS, is often associated with 
psychological difficulties, that in concert with FMS can modify both the apparent phenotypic 
presentation and severity of clinical disease by inflating subjective symptoms.
For years, working at the Cleveland Clinic Foundation, a tertiary care practice, I  evaluated 
RA patients who were referred because they were refractory to treatment, so-called 
“ resistant arthritis” [23]. At final diagnosis, I could usually classify these patients into 
three categories:
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The majority either had only FMS, or did have RA, but the resistant symptoms were unrelated 
to RA and consistent with bursitis, tendinitis, OA, and especially FMS. In the third category, 
a very few had truly resistant RA disease activity.
At first blush, we might ask, “How is this possible?” When we learn that most  rheumatologists 
no longer perform joint counts at office evaluation, we might better understand [24]. By 
 failing to perform joint counts, they rely heavily on subjective symptoms such as the patient 
global assessment (PtGA) and patient evaluation of joint pain. Even when joint counts are 
included in the evaluation, mistakes can be made. Diffuse pain is by definition nonarticular, 
but can also include the joints [25–27], manifesting as a higher TJC. Comorbid FMS is also 
associated with increased duration and severity of morning stiffness, lower values for func-
tion measured as the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the 
physical components of the SF-36 as well as diminished quality of life measured by the mental 
 components of the same instrument [28, 29]. It is important to note a key diagnostic find-
ing; in these reports, comorbid FMS did not usually associate with or obfuscate the  swollen 
joint count (SJC) or acute phase reactants such as erythrocyte sedimentation rate (ESR), or 
c-reactive protein (CRP).
Comorbid FMS gives rise to enhanced pain sensitivity. The mechanism responsible for 
enhanced pain sensitivity is mediated in the central nervous system, facilitated by  depression/
anxiety [30–33]. In a cross-sectional analysis of a cohort of 305 FMS patients, depression 
showed the highest association with core FMS signs and symptoms [34]. The degree of 
depression showed a dose relationship with life-long numbers of TPs [35] and was responsi-
ble for the process of comorbid FMS in RA [36]. In a unique analysis using advanced Bayesian 
filtering of 247 diseases among 117,392 participants, depression was shown to be a primary 
comorbidity associated with FMS [37].
In summary, the effects of comorbid FMS on RA disease activity measures are many. It is asso-
ciated with disproportionate elevation of PtGA and TJC [26, 28, 29, 38, 39]. The  elevation of the 
subjective components of the DAS model indices inflates the total score. It is not  surprising 
that in a recent analysis of change in disease status in patients with multiple comorbidities, 
PtGA best correlated with the other subjective variables, pain, and fatigue, which are also 
disproportionately elevated by comorbid FMS [40].
1.2. The spondyloarthropathies (SpA)
Diagnostic confusion is a larger problem in patients with SpA. An editorial reviewed the 
 similarities between SpA and FMS, which included overlap of disease activity measures, 
found in patients with presumed enthesitis [41]. They asserted that FMS tender points (TPs) 
were anatomically located near or at enthesitis sites, which was confirmed in a separate 
study [8].
Because, as will be described, comorbid FMS disproportionately increases the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score 
(ASDAS), Bath Ankylosing Spondylitis Functional Index (BASFI), and Ankylosing Spondylitis 
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Quality of Life (ASQoL), it not only increases diagnostic confusion, but also interferes with 
accurate assessment of disease activity, disability, and quality of life. A strong case can be 
made for including FMS in the differential diagnosis of SpA.
Similarity between the two conditions was confirmed by Ablin and colleagues who 
approached the problem from the other perspective [42]. They carefully evaluated 99 patients 
who met 1990 ACR criteria for FMS, to determine whether some might also be classified as 
SpA. Ten patients fulfilled ASAS criteria for the diagnosis of axial SpA: eight of whom ful-
filled the criteria based on MRI findings diagnostic of sacroiliitis, while two patients with 
negative MRI results fulfilled ASDAS criteria based on a positive HLA–B27 and the presence 
of SpA features.
One of the first studies to analyze phenotypic modification of ankylosing spondylitis by 
comorbid FMS was a cross-sectional study of 36 patients, 18 of each gender [43]. About 50% of 
women satisfied the criteria for comorbid FMS, whereas no males did. In this study, FMS cor-
related with the mean number of enthesitis sites. Higher BASDAI in women showed strong 
association with both the FMS incidence and a higher number of tender points. The perceived 
disability measured by BASFI was also significantly increased in patients with comorbid 
FMS. No association was found for the presence of FMS and the severity of physical findings 
or the ESR.
Interference with outcome measures was probably best demonstrated in an earlier study by 
Heikkila and colleagues [44]. They administered the BASDAI and BASFI, among other com-
posite measures, to 24 women with SpA and 70 patients with FMS. The BASFI function dem-
onstrated greater disability in the FMS group compared to SpA women.
If one is to rely on any one test in SpA with comorbid FMS, the ASDAS has been shown to be 
less obfuscated by comorbid FMS [45, 46]. These relationships to disease activity measures 
and a prevalence of FMS as high as 30% were largely confirmed by other studies [47–49]
The relatively high prevalence of FMS is not surprising, given the high prevalence of 
 psychiatric problems in the SpA’s estimated to be 40–50% [50]. When present, they similarly 
obfuscate measures of severity [50, 51]. “Patients with high risk for depression and anxiety 
had higher scores in BASDAI, BASFI, ASDAS-CRP, and also poorer scores for the pain visual 
analog scale (PVAS) and ankylosing spondylitis quality of life score” [51].
In summary, comorbid FMS complicates both diagnosis and estimation of disease activity 
in SpA. It follows that treatment decisions may also be obfuscated when FMS falsely inflates 
the BASDAI, PtGA, and BASFI [47]. This may lead to more frequent but inappropriate use of 
biologic agents, as it did in RA [52].
1.3. SLE
As discussed in the introduction, the prevalence of FMS in SLE has been reported to be at least 
as high as in RA ranging from five to 65% with a mean of ~30% [31, 53–65]. The core symp-
toms of FMS, diffuse pain, fatigue (low energy), cognitive difficulties, sleep disturbance, and 
depression will, of course, always be encountered in FMS comorbid disease.
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Fatigue is present in at least 80% of patients with FMS. In a cross-sectional analysis of 100 
SLE patients, fatigue correlated best with the presence of FMS, followed by depression and 
 elevated PtGA [63]. In a very careful prospective blisibimod trial in SLE, improvement of 
fatigue was not clinically significant and correlated weakly only with SLE disease activity [66]. 
They hypothesized that, “…fatigue in SLE is multifactorial, with the ‘non- SLE’  component 
(including depression and fibromyalgia) less amenable to change during the trial.”
Depression is a common comorbidity in unselected SLE cohorts ranging from 17 to 71% 
[31, 67]. The high prevalence of depression in SLE may help to explain the high prevalence 
of FMS. In a cohort study of 84 SLE patients, comorbid FMS was associated with anxiety 
and depression [60]. In a larger cohort of 276 SLE patients, the strongest association with 
both FMS and SLE/FM-like manifestations was a self-reported history of anxiety or affective 
 disorder [65].
Quality of life (QoL) is closely associated with anxiety and depression in SLE [67]. In a study 
specifically designed to analyze health-related quality of life (HRQOL) in 138 SLE patients, 
all disease-specific HRQOL domains were significantly inversely correlated with disease 
 activity, damage, depression, and the presence of FMS [59]. Comorbid FMS and depression 
was also shown to diminish QoL in two additional large SLE cohorts [68, 69].
Most analyses of health status in SLE have demonstrated that comorbid FMS is associated 
with increased disability [57, 60, 61, 65]. In a particularly important analysis, the number of 
tender points correlated with increasing disability demonstrating a dose effect [62].
Just as in RA and SpA, comorbid FMS modifies SLE disease activity measures. Sometimes, 
older papers are the best. In a study, published in 1994, the authors reported and analyzed 
differences in a cross-sectional analysis of 102 SLE patients [61]. “Twenty-two SLE patients 
(22%) met the American College of Rheumatology criteria for FMS, and another 24 (23%) had 
clinical FMS but did not meet the classification criteria,” SLE patients with FMS and prob-
able FMS (6–10 TPs) presented significantly higher Systemic Lupus Activity Measure (SLAM) 
scores. When the SLAM was modified by removing all subjective symptoms, neither category 
scored higher than SLE without FMS. This was also true for laboratory tests. Finally, patients 
who met criteria for FMS were much more likely to be unable to perform daily activities. 
By modifying components of disease severity composite indices, this early paper prefigured 
recent work in RA that employed the objective M-DAS or subjective DAS28-P [70, 71].
In the same year, Morand and colleagues reported the same phenomena in 87 SLE patients, 
22, with FMS [57]. Manifestations of biological SLE disease activity, measured by the severity 
of specific organ system involvement, showed no difference between groups. The Systemic 
Lupus Activity Measurement scores were not significantly different. However, frequency 
of glucocorticoid use, antibodies to double-stranded DNA, the presence of at least four 
ACR  criteria for SLE, and physician’s global assessment (PhGA) were higher in the patients 
 without FMS indicating more severe objective, biological disease in this subset. This analysis 
suggested that comorbid FMS in SLE can inappropriately increase the SLAM score.
Other indices appear to be relatively unaffected. In a cross-sectional analysis of 119 SLE 
patients, patients with FMS showed no effect on Systemic Lupus Erythematosus Activity 
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Index (SLEDAI) or Damage index, but did show poorer scores in all eight domains of the 
Short Form-36 [58]. The SLEDAI SLE disease activity score was also not influenced by FMS in 
another cohort of 100 SLE patients [63]. In another analysis of a much larger population of 458 
SLE patients, comorbid FMS did not affect the 16-item SLE Symptom Scale [72]. These authors 
did not evaluate other composite indices.
Comorbid FMS signs and symptoms may also complicate the diagnostic process. For 
instance, when 149 presumed SLE patients with up to 5 years of disease duration were 
 rigorously analyzed, 22 (14.3%) had only FMS with positive antinuclear antibodies (ANA) [73]. 
Depression, anxiety, fatigue, and sleep disturbance were the prominent symptoms in this 
group. Symptoms that indicated SLE included swollen joints, skin lesions, alopecia, renal 
disease, and serositis [72, 73].
The anti-nuclear antibody (ANA) test can be very confusing from the perspective of  diagnosis. 
The high sensitivity of most and relatively low specificity of some ANA tests is  problematic. 
Nonspecific (+) ANA in any titer can be found in roughly 30% of the general population, more 
likely in women and individuals 65 years and older [74–77]. Even titers as high as 1:320 are 
likely to be false positive in some settings, such as hospitalized patients [77]. The ANA is posi-
tive in low titer in at least 38% of individuals with FMS alone [78]. Furthermore, FMS patients 
with positive ANA tests are no more likely to have symptoms of autoimmune  rheumatic disease 
than ANA-negative patients [53, 79], nor are they likely to later develop symptoms of an autoim-
mune disease in the future [80].
In summary, comorbid FMS inappropriately inflates some measures of SLE biological 
 disease and, when patient with FMS have positive ANA testing, can interfere with diagnos-
tic precision.
1.3.1. Parsing comorbid FMS: the RA models
Comorbid FMS in other diseases is not necessarily occult. It can be discovered both by clinical 
maneuvers and the use of validated questionnaires.
A very important study provided a basis for these maneuvers. The DAS28 was administered 
to 62 patients with RA and 26 patients with FMS alone [81]. Both groups had total scores 
 consistent with moderate RA disease activity. But the component values were very different; 
the RA patients scored uniformly high for all components while the FMS cohort scored very 
high for the subjective TJC and PtGA and low on the objective SJC and ESR.
One clinical maneuver, which can be applied in RA, makes use of that observation;  comorbid 
FMS disproportionally raises the TJC relative to the SJC. Comorbid FMS is likely to be 
 present if the numerical difference is ≥7 when the SJC is subtracted from the TJC (39 Pollard). 
Alternatively, ratios of the TJC compared to the SJC may be used [30, 82]. In the third of 
these studies, depression, and by inference, pain, was shown to be a mediator of higher 
tender-to-swollen joint ratios [30].
To summarize, these last few studies have demonstrated that when the TJC is disproportion-
ally higher than the SJC in RA: (1) comorbid pain amplification/FMS is a likely comorbidity, 
(2) biological RA disease activity, measured as the SJC and CRP/ESR, may be lower than 
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indicated by the DAS28 composite score, and (3) joint count discordance should initiate a 
search for depression or other comorbidities that contribute to pain.
Two other RA studies created clinical maneuvers by modification of the DAS-model indices. 
In the first, the models were changed by removing the TJC and PTGA and adding the PhGA 
[70]. This “objective” DAS, termed the M-DAS, correlated better than the original DAS model 
with longitudinal magnetic resonance imaging (MRI) and radiographic outcome, providing 
better construct validity.
An alternative modification, DAS28-P, was created to reflect the proportion of the DAS28 
derived from the PtGA and TJC [71]. This “subjective” index model correlated with higher 
articular and nonarticular pain pressure thresholds, fatigue, poorer mental health, and most 
importantly, the presence of FMS.
Another instrument that has been specifically designed to recognize FMS alone or as a comor-
bid condition is the Polysymptomatic Distress Score (PSD) [83]. This instrument incorporates 
questions about pain and core symptoms of FMS, and has been demonstrated to measure 
comorbid FMS prevalence and severity in RA [84].
In summary, both comorbid FMS and depression disproportionately inflate symptoms of 
pain and fatigue which, in turn, amplify PtGA and other subjective patient-report-only indi-
ces. These disproportionately higher subjective components then raise the total score of the 
composite index, falsely indicating higher biological disease. Biological disease activity is not 
worsened by comorbid FMS; it is only the measures, the ratings, that are obfuscated by FMS.
1.3.2. Remedies
One appropriate approach to the comorbid FMS problem in all of these diseases might be 
to construct two separate indices: one comprised of symptoms that arise from patient per-
ceptions of pain, distress, and fatigue (PtGA, TJC, number of enthesitis sites, disability) and 
the other measures of objective inflammatory burden (acute phase reactants, SJC) and target 
organ damage. If these two separate indices are discordant, those symptoms and signs of FMS 
or autoimmune biological disease activity are treated separately and differently. Treatments 
for FMS and psychological disorders versus biological disease activity are distinctly different. 
This strategy should limit potential inappropriate over-treatment of the primary disease and 
provide better control of pain, distress, and fatigue, factors that are not necessarily intrinsi-
cally related to biological disease activity.
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